The FDA has set a Feb. 21 target decision on the Bysanti NDA. ・Vanda submitted the NDA in March 2025 for Bysanti to treat acute bipolar I disorder and schizophrenia. ・In May, the FDA said the ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025.

WASHINGTON, May 2, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2025 on Wednesday, May 7, 2025, after the market ...

WASHINGTON, May 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VNDA) today announced financial and operational results for the first quarter ended March 31, 2025. "Vanda has entered a new growth ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2025 Earnings Call Transcript February 11, 2026 Vanda Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $-2.39 EPS, expectations were ...

The D.C. biotech also filed a shelf registration statement for $200 million, opening the door for it to raise that money over ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full ...

Presentation Title: "Translating IGHMBP2 Variants with a CMT2S Patient-specific Organ-on-a-chip Model: Personalized Medicine ASO-based Therapeutic Rescue" Poster Presentation Session: P-12 Poster ...

WASHINGTON, Nov. 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Stifel 2025 Healthcare Conference in New York City ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-second-quarter-2025-financial-results-302518338 ...

Our fourth quarter and full year 2025 results were released this afternoon and are available on the SEC’s EDGAR system and on our website, Joining me on today’s call is Mihael H. Polymeropoulos, our ...

Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024 Full year 2025 total revenues increased by 9% to $216.1 million ...